Outcome Predictors of Gillian Barrie Syndrome In Pediatrics
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Assiut University
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months
Study Overview
Brief Summary
This study analyze clinical and biological factors influencing disease course and outcome. Some research identified factors like disease severity, sensory symptoms, and autonomic instability as indicators of poor outcome. Ongoing research aims to develop accurate predictive models for improved treatment and care.
Detailed Description
Guillain-Barré Syndrome (GBS) is the most common cause of acute flaccid paralysis in children worldwide, often presenting with progressive weakness, areflexia, and varying degrees of autonomic and cranial nerve involvement. It is an immune-mediated disorder, commonly triggered by preceding infections such as Campylobacter jejuni, cytomegalovirus, or Epstein-Barr virus. Pediatric patients generally have a better prognosis than adults, yet a significant proportion still suffer from residual weakness or prolonged recovery. Understanding early predictors of outcome is essential for optimizing treatment and counseling families.[1][2] Several clinical and laboratory factors have been identified as potential predictors of poor outcomes in pediatric GBS. These include rapid progression to peak weakness, requirement of mechanical ventilation, presence of cranial nerve involvement (especially bulbar palsy), autonomic dysfunction, and the axonal subtypes of GBS on nerve conduction studies. Early identification of such factors allows for more aggressive supportive care and closer monitoring.[3][4][5] Electrophysiological classification also plays a vital role in predicting outcomes. Children with acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN) tend to have a slower and less complete recovery compared to those with acute inflammatory demyelinating polyneuropathy (AIDP). Furthermore, delayed initiation of immunotherapy such as intravenous immunoglobulin (IVIG) or plasma exchange may be associated with poorer prognosis.[6][7] Biomarkers like elevated cerebrospinal fluid (CSF) protein without pleocytosis (albuminocytologic dissociation) are typical in GBS but do not necessarily predict outcome. However, higher CSF protein levels in the early phase may correlate with more severe disease. Some recent studies have also suggested that MRI enhancement of spinal nerve roots may be associated with disease severity, although its prognostic value remains under investigation.[8][9] In conclusion, recognizing early outcome predictors in pediatric GBS is crucial for timely intervention, resource allocation, and family support. Although many children recover fully, identifying those at risk for complications can improve both short- and long-term care strategies.[2][3][10]
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 1 Month to 18 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All Pediatric patients (1 month to 18 years old) admitted with acute flaccid ascending paralysis and diagnosed as GBS.
- •Consent obtained from parents or legal guardians for participation and follow-up.
Exclusion Criteria
- •Children with pre-existing neuromuscular disorders. Patients with incomplete medical records or those lost to follow-up. Cases diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP).
Outcomes
Primary Outcomes
Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months
Time Frame: first 3 months after diagnosis
Proportion of pediatric patients with Guillain-Barré Syndrome achieving full recovery, as assessed by the Hughes Functional Grading Scale, within 3 months of diagnosis.
Secondary Outcomes
No secondary outcomes reported
Investigators
Nourhan Maher Fawzy
principal investigator
Assiut University
